Miragen Therapeutics Inc (MGEN) - Financial and Strategic SWOT Analysis Review

  • ID: 4278624
  • SWOT Analysis
  • 43 pages
  • GlobalData
1 of 5

FEATURED COMPANIES

  • Bri
  • Celgene Corp
  • InteRNA Technologies BV
  • Ionis Pharmaceuticals Inc
  • Merck & Co Inc
  • Microlin Bio Inc
  • MORE
Miragen Therapeutics Inc (MGEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Miragen Therapeutics, Inc. (Miragen), formerly Signal Genetics Inc, is a clinical stage biopharmaceutical company. It discovers and develops RNA-targeted therapeutics with a focus on microRNAs and their role in diseases. The company’s product candidates, MRG-106 and MRG-201 are in Phase 1 clinical trials. Miragen’s clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155; and clinical product candidate for the treatment of pathological fibrosis, MRG-201, is a replacement for miR-29. It is also developing a pipeline of pre-clinical product candidates. Miragen is headquartered in Boulder, Colorado, the US.

Miragen Therapeutics Inc Key Recent Developments

Aug 11,2017: miRagen Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
May 10,2017: miRagen Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
Mar 31,2017: miRagen Therapeutics Provides Corporate Update
Nov 29,2016: miRagen Therapeutics Expands Executive Leadership Team
Sep 09,2016: miRagen Therapeutics Appoints Kevin Koch, Ph.D., to Its Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bri
  • Celgene Corp
  • InteRNA Technologies BV
  • Ionis Pharmaceuticals Inc
  • Merck & Co Inc
  • Microlin Bio Inc
  • MORE
Section 1 - About the Company
  • Miragen Therapeutics Inc - Key Facts
  • Miragen Therapeutics Inc - Key Employees
  • Miragen Therapeutics Inc - Key Employee Biographies
  • Miragen Therapeutics Inc - Major Products and Services
  • Miragen Therapeutics Inc - History
  • Miragen Therapeutics Inc - Company Statement
  • Miragen Therapeutics Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Miragen Therapeutics Inc - Business Description
  • Miragen Therapeutics Inc - Corporate Strategy
  • Miragen Therapeutics Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Miragen Therapeutics Inc - Strengths
  • Miragen Therapeutics Inc - Weaknesses
  • Miragen Therapeutics Inc - Opportunities
  • Miragen Therapeutics Inc - Threats
  • Miragen Therapeutics Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Miragen Therapeutics Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017
  • Miragen Therapeutics Inc, Medical Equipment, Deals By Type, 2011 to YTD 2017
  • Miragen Therapeutics Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Aug 11, 2017: miRagen Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
  • May 10, 2017: miRagen Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
  • Mar 31, 2017: miRagen Therapeutics Provides Corporate Update
  • Nov 29, 2016: miRagen Therapeutics Expands Executive Leadership Team
  • May 26, 2016: Signal Genetics Receives Extension to Comply with Nasdaq Continued Listing Requirement
  • May 16, 2016: Signal Genetics Highlights Recent Achievements And Reports First Quarter 2016 Financial Results
  • Mar 16, 2016: Signal Genetics Highlights Recent Achievements and Reports Fourth Quarter and Full-Year 2015 Financial Results
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • Miragen Therapeutics Inc, Key Facts
  • Miragen Therapeutics Inc, Key Employees
  • Miragen Therapeutics Inc, Key Employee Biographies
  • Miragen Therapeutics Inc, Major Products and Services
  • Miragen Therapeutics Inc, History
  • Miragen Therapeutics Inc, Subsidiaries
  • Miragen Therapeutics Inc, Key Competitors
  • Miragen Therapeutics Inc, Ratios based on current share price
  • Miragen Therapeutics Inc, Annual Ratios
  • Miragen Therapeutics Inc, Annual Ratios (Cont...1)
  • Miragen Therapeutics Inc, Interim Ratios
  • Miragen Therapeutics Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017
  • Miragen Therapeutics Inc, Medical Equipment, Deals By Type, 2011 to YTD 2017
  • Miragen Therapeutics Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Miragen Therapeutics Inc, Performance Chart (2012 - 2016)
  • Miragen Therapeutics Inc, Ratio Charts
  • Miragen Therapeutics Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017
  • Miragen Therapeutics Inc, Medical Equipment, Deals by Type, 2011 to YTD 2017
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • RXi Pharmaceuticals Corp
  • Regulus Therapeutics Inc
  • RaNA Therapeutics, Inc.
  • Mirna Therapeutics Inc
  • Microlin Bio Inc
  • Merck & Co Inc
  • Ionis Pharmaceuticals Inc
  • InteRNA Technologies BV
  • Dicerna Pharmaceuticals Inc
  • Celgene Corp
  • Bri
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll